Class information for:
Level 1: DPP 4 INHIBITOR//EXENATIDE//LIRAGLUTIDE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
580 3286 44.1 85%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
176 3       DIABETES CARE//ENDOCRINOLOGY & METABOLISM//TYPE 2 DIABETES 58057
1167 2             GLUCAGON LIKE PEPTIDE 1//GLP 1//INCRETIN 9383
580 1                   DPP 4 INHIBITOR//EXENATIDE//LIRAGLUTIDE 3286

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DPP 4 INHIBITOR authKW 1828627 9% 70% 282
2 EXENATIDE authKW 1699020 9% 63% 291
3 LIRAGLUTIDE authKW 1539446 8% 60% 277
4 DIPEPTIDYL PEPTIDASE 4 INHIBITOR authKW 1480251 7% 73% 219
5 SITAGLIPTIN authKW 1427845 8% 58% 263
6 VILDAGLIPTIN authKW 1144445 5% 68% 180
7 GLP 1 RECEPTOR AGONIST authKW 946614 4% 77% 132
8 INCRETIN authKW 919934 9% 34% 290
9 LINAGLIPTIN authKW 895596 4% 82% 117
10 SAXAGLIPTIN authKW 839969 4% 77% 118

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Endocrinology & Metabolism 53825 49% 0% 1613
2 Pharmacology & Pharmacy 4323 23% 0% 752
3 Medicine, General & Internal 2231 13% 0% 440
4 Cardiac & Cardiovascular System 1210 9% 0% 287
5 Medicine, Research & Experimental 774 7% 0% 225
6 Peripheral Vascular Diseases 361 4% 0% 126
7 Primary Health Care 291 1% 0% 34
8 Health Care Sciences & Services 43 1% 0% 40
9 Physiology 42 2% 0% 76
10 Toxicology 41 2% 0% 62

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 LILLY DIABET 103400 0% 70% 16
2 THER EUT AREA METAB 102911 0% 92% 12
3 DIABET METAB TRANSLAT MED UNIT 62446 0% 61% 11
4 DIABET AGCY 38564 1% 23% 18
5 STUDY GRP DIABET COMM 37163 0% 100% 4
6 DIABET NUTR METAB DISORDERS 32726 1% 15% 23
7 DIABET 32526 6% 2% 181
8 SECT GERIATR CARDIOL MED 31286 0% 42% 8
9 CIC INSERM ILCV 27872 0% 100% 3
10 MONGOLIAN PHARMACEUT PREPARAT 27872 0% 100% 3

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DIABETES OBESITY & METABOLISM 437711 10% 15% 322
2 DIABETES THERAPY 138722 2% 29% 52
3 CARDIOVASCULAR DIABETOLOGY 47997 2% 6% 80
4 JOURNAL OF DIABETES INVESTIGATION 47348 2% 9% 54
5 DIABETES CARE 22021 5% 1% 165
6 DIABETOLOGIE UND STOFFWECHSEL 15193 1% 8% 21
7 JOURNAL OF DIABETES 11613 1% 5% 24
8 DIABETES & VASCULAR DISEASE RESEARCH 11117 1% 5% 22
9 DIABETES STOFFWECHSEL UND HERZ 10623 1% 7% 17
10 CURRENT MEDICAL RESEARCH AND OPINION 9829 2% 2% 69

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 DPP 4 INHIBITOR 1828627 9% 70% 282 Search DPP+4+INHIBITOR Search DPP+4+INHIBITOR
2 EXENATIDE 1699020 9% 63% 291 Search EXENATIDE Search EXENATIDE
3 LIRAGLUTIDE 1539446 8% 60% 277 Search LIRAGLUTIDE Search LIRAGLUTIDE
4 DIPEPTIDYL PEPTIDASE 4 INHIBITOR 1480251 7% 73% 219 Search DIPEPTIDYL+PEPTIDASE+4+INHIBITOR Search DIPEPTIDYL+PEPTIDASE+4+INHIBITOR
5 SITAGLIPTIN 1427845 8% 58% 263 Search SITAGLIPTIN Search SITAGLIPTIN
6 VILDAGLIPTIN 1144445 5% 68% 180 Search VILDAGLIPTIN Search VILDAGLIPTIN
7 GLP 1 RECEPTOR AGONIST 946614 4% 77% 132 Search GLP+1+RECEPTOR+AGONIST Search GLP+1+RECEPTOR+AGONIST
8 INCRETIN 919934 9% 34% 290 Search INCRETIN Search INCRETIN
9 LINAGLIPTIN 895596 4% 82% 117 Search LINAGLIPTIN Search LINAGLIPTIN
10 SAXAGLIPTIN 839969 4% 77% 118 Search SAXAGLIPTIN Search SAXAGLIPTIN

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 SCHEEN, AJ , (2015) A REVIEW OF GLIPTINS FOR 2014.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 16. ISSUE 1. P. 43 -62 131 87% 25
2 ROTZ, ME , GANETSKY, VS , SEN, S , THOMAS, TF , (2015) IMPLICATIONS OF INCRETIN-BASED THERAPIES ON CARDIOVASCULAR DISEASE.INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. VOL. 69. ISSUE 5. P. 531 -549 133 92% 5
3 SCHEEN, AJ , (2015) SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR TREATING TYPE 2 DIABETES.EXPERT OPINION ON DRUG SAFETY. VOL. 14. ISSUE 4. P. 505 -524 114 92% 15
4 BAETTA, R , CORSINI, A , (2011) PHARMACOLOGY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS SIMILARITIES AND DIFFERENCES.DRUGS. VOL. 71. ISSUE 11. P. 1441 -1467 111 83% 98
5 CHEN, XW , HE, ZX , ZHOU, ZW , YANG, TX , ZHANG, XJ , YANG, YX , DUAN, W , ZHOU, SF , (2015) CLINICAL PHARMACOLOGY OF DIPEPTIDYL PEPTIDASE 4 INHIBITORS INDICATED FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS.CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. VOL. 42. ISSUE 10. P. 999 -1024 123 80% 7
6 OSTERGAARD, L , FRANDSEN, CS , MADSBAD, S , (2016) TREATMENT POTENTIAL OF THE GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS: A REVIEW.EXPERT REVIEW OF CLINICAL PHARMACOLOGY. VOL. 9. ISSUE 2. P. 241 -265 105 88% 2
7 LI, L , LI, SY , DENG, K , LIU, JL , VANDVIK, PO , ZHAO, PJ , ZHANG, LH , SHEN, JT , BALA, MM , SOHANI, ZN , ET AL (2016) DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND RISK OF HEART FAILURE IN TYPE 2 DIABETES: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED AND OBSERVATIONAL STUDIES.BMJ-BRITISH MEDICAL JOURNAL. VOL. 352. ISSUE . P. - 61 85% 19
8 FILIPPATOS, TD , ATHYROS, VG , ELISAF, MS , (2014) THE PHARMACOKINETIC CONSIDERATIONS AND ADVERSE EFFECTS OF DDP-4 INHIBITORS.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 10. ISSUE 6. P. 787 -812 137 72% 11
9 SCHEEN, AJ , (2013) CARDIOVASCULAR EFFECTS OF GLIPTINS.NATURE REVIEWS CARDIOLOGY. VOL. 10. ISSUE 2. P. 73 -84 101 81% 58
10 KEATING, GM , (2014) VILDAGLIPTIN: A REVIEW OF ITS USE IN TYPE 2 DIABETES MELLITUS.DRUGS. VOL. 74. ISSUE 5. P. 587-610 109 88% 12

Classes with closest relation at Level 1


Rank Class id link
1 376 GLUCAGON LIKE PEPTIDE 1//GLP 1//INCRETIN
2 1970 INSULIN GLARGINE//BIPHASIC INSULIN ASPART 30//INSULIN INITIATION
3 3369 DIPEPTIDYL PEPTIDASE IV//CD26//DIPEPTIDYL PEPTIDASE
4 9043 SGLT2 INHIBITOR//DAPAGLIFLOZIN//CANAGLIFLOZIN
5 22786 GLICLAZIDE//ARTIFICIAL CELL MICROENCAPSULATION//BIOTECHNOL DRUG DEV
6 3093 PIOGLITAZONE//THIAZOLIDINEDIONES//ROSIGLITAZONE
7 8850 METFORMIN//LACTIC ACIDOSIS//BIGUANIDES
8 25009 ANTIDIABETIC PHARMACOTHERAPY//A HEFT//ACORN CSD
9 16225 REPAGLINIDE//NATEGLINIDE//MITIGLINIDE
10 17766 GLYCATED ALBUMIN//BURNT OUT DIABETES//DIABET CLIN SERV UNIT

Go to start page